Literature DB >> 28301105

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

Maurizio Mennini1,2, Lamia Dahdah1, Alessandro Fiocchi1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28301105     DOI： 10.1056/NEJMc1700366

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

1.  Cicatricial ectropion in a patient treated with dupilumab.

Authors:  Alexander C Barnes; Alexander D Blandford; Julian D Perry
Journal:  Am J Ophthalmol Case Rep       Date:  2017-06-22

Review 2.  Leveraging Multilayered "Omics" Data for Atopic Dermatitis: A Road Map to Precision Medicine.

Authors:  Debajyoti Ghosh; Jonathan A Bernstein; Gurjit K Khurana Hershey; Marc E Rothenberg; Tesfaye B Mersha
Journal:  Front Immunol       Date:  2018-12-12       Impact factor: 7.561

3.  Dupilumab-associated blepharoconjunctivitis.

Authors:  Sefy A Paulose; Suzanne W Sherman; Lora R Dagi Glass; Leejee H Suh
Journal:  Am J Ophthalmol Case Rep       Date:  2019-09-05

Review 4.  A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis.

Authors:  Gaurav Agnihotri; Katherine Shi; Peter A Lio
Journal:  Drugs R D       Date:  2019-12

5.  Conjunctivitis in dupilumab clinical trials.

Authors:  B Akinlade; E Guttman-Yassky; M de Bruin-Weller; E L Simpson; A Blauvelt; M J Cork; E Prens; P Asbell; E Akpek; J Corren; C Bachert; I Hirano; J Weyne; A Korotzer; Z Chen; T Hultsch; X Zhu; J D Davis; L Mannent; J D Hamilton; A Teper; H Staudinger; E Rizova; G Pirozzi; N M H Graham; B Shumel; M Ardeleanu; A Wollenberg
Journal:  Br J Dermatol       Date:  2019-05-07       Impact factor: 9.302

Review 6.  Squamous Cell Carcinoma Antigen 2 (SCCA2, SERPINB4): An Emerging Biomarker for Skin Inflammatory Diseases.

Authors:  Kenji Izuhara; Yukie Yamaguchi; Shoichiro Ohta; Satoshi Nunomura; Yasuhiro Nanri; Yoshinori Azuma; Noriko Nomura; Yasuhiko Noguchi; Michiko Aihara
Journal:  Int J Mol Sci       Date:  2018-04-06       Impact factor: 5.923

Review 7.  Treatment of Atopic Dermatitis with Biologic Drugs.

Authors:  Gabriella Fabbrocini; Maddalena Napolitano; Matteo Megna; Nicola Balato; Cataldo Patruno
Journal:  Dermatol Ther (Heidelb)       Date:  2018-09-04

8.  Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion.

Authors:  J P Thyssen; M S de Bruin-Weller; A S Paller; Y A Leshem; C Vestergaard; M Deleuran; A M Drucker; R Foelster-Holst; C Traidl-Hoffmann; K Eyerich; A Taieb; J C Su; T Bieber; M J Cork; L F Eichenfield; E Guttman-Yassky; A Wollenberg
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-05-06       Impact factor: 6.166

9.  Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience.

Authors:  Silvia Ferrucci; Giovanni Casazza; Luisa Angileri; Simona Tavecchio; Francesca Germiniasi; Emilio Berti; Angelo Valerio Marzano; Giovanni Genovese
Journal:  J Clin Med       Date:  2020-03-13       Impact factor: 4.241

10.  Dupilumab-Associated Mucin Deficiency (DAMD).

Authors:  Brad P Barnett; Natalie A Afshari
Journal:  Transl Vis Sci Technol       Date:  2020-02-25       Impact factor: 3.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.